Sleep Duration and “on” Time during Different Periods of the Day and Night in Patients with Advanced Parkinson's Disease Receiving Adjunctive Ropinirole Prolonged Release

Table 1

Demographics and baseline characteristics of patients (intent-to-treat population).

	Ropinirole prolonged release (𝑛=201)	Placebo (𝑛=190)
Age, years	66.3 (9.17)	66.0 (9.74)
Women, n (%)	84 (42)	61 (32)
Age at onset of PD, years	57.6(10.53)^a	57.3(10.74)^b
Duration of PD, years	8.6(4.76)^a	8.6(5.15)^b
Duration of L-dopa treatment, years	6.5(4.45)^c	6.6(4.33)^d
L-dopa dose, mg/day	824(424.4)^c	776 (357.3)
Total daily awake time spent “on”, hours	9.0 (2.75)	9.1 (2.69)
Amount of awake time spent “on”, hours
Daytime (8 am–10 pm)	7.9(2.24)^e	7.8(2.13)^f
Morning (8 am–1 pm)	3.0(1.06)^e	2.9(0.97)^f
Afternoon (1 pm–6 pm)	2.7(0.90)^e	2.7(0.87)^f
Evening (6 pm–10 pm)	2.2(0.93)^e	2.2(0.95)^f
Percentage awake time spent “on”
Nighttime (10 pm–8 am)	40.0(25.79)^e	39.9(28.49)^f
Early morning (5 am–10 am)	50.2(25.20)^e	47.6(24.99)^f
Patients “on” on waking in the morning, n (%)^g	28(15)^d	24(14)^h
Duration of sleep time, hours
Daytime (8 am–10 pm)	0.8(0.99)^e	0.9(1.07)^f
Nighttime (10 pm–8 am)	7.1(1.48)^e	7.1(1.31)^f
Patients with no awakenings/night, n (%)^g	110(59)^d	86(50)^h

^a𝑛=200; ^b𝑛=188; ^c𝑛=199; ^d𝑛=187; ^e𝑛=190; ^f𝑛=175; ^gweek 0 data (two diary card days from the second week of the baseline period)), ^h𝑛=173.
All values are mean (SD) unless stated otherwise.